VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents.
The sector offers a safe haven from macroeconomic and earnings concerns ahead of quarterly results from European companies, according to the Wall Street bank.
Argenx stock lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of.